Hospital
Uofl Health-Shelbyville INC
Uofl Health-Shelbyville INC was paid $18.54M by Medicaid between Jan 2018 and Dec 2024, across 160 billing codes. Its largest line is 99285, emergency room visit (most serious) — 18% of everything it billed.
33Billing provider infoUOFL HEALTH-SHELBYVILLE INC
SHELBYVILLE, KY 40065
SHELBYVILLE, KY 40065
33aNPI1497397053assigned 10/15/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.54M
24GClaims346,158
24DCodes billed160
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#25 of 36
Median peer was paid$36.08M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,476 | $3.17M | |
| 2019 | 54,795 | $2.49M | |
| 2020 | 46,033 | $2.29M | |
| 2021 | 50,819 | $2.83M | |
| 2022 | 52,628 | $3.27M | |
| 2023 | 50,147 | $2.93M | |
| 2024incomplete | 27,260 | $1.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 9,831 | 6,761 | $3.36M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 12,508 | 10,521 | $3.08M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 13,316 | 11,679 | $2.36M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.1% | 3,265 | 2,843 | $1.13M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 3,101 | 2,567 | $681K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.1% | 1,920 | 1,682 | $576K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 4,347 | 3,945 | $484K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.5% | 10,840 | 2,644 | $465K |
| 87631 | 2.1% | 3,496 | 3,206 | $389K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 8,556 | 6,961 | $349K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 893 | 732 | $332K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 14,868 | 6,243 | $331K |
148 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 10,888 | $317K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 7,101 | $277K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 6,028 | $248K |
| 80053 | Comprehensive metabolic panel | 1.0% | 20,439 | $192K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,805 | $171K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,402 | $166K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,544 | $165K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,199 | $160K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,297 | $158K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 673 | $154K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,745 | $131K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,576 | $125K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,817 | $124K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,736 | $122K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,885 | $103K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 645 | $98K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,715 | $97K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,208 | $89K |
| 87634 | <1% | 3,521 | $87K | |
| 73610 | <1% | 686 | $85K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 232 | $85K |
| 96376 | <1% | 1,843 | $80K | |
| 72100 | <1% | 961 | $79K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,262 | $75K |
| 73630 | <1% | 721 | $75K | |
| G0378 | Hospital observation service, per hour | <1% | 1,345 | $74K |
| 84484 | <1% | 6,518 | $71K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,629 | $67K |
| 83880 | <1% | 2,568 | $66K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 292 | $65K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,433 | $55K |
| 97161 | <1% | 1,111 | $48K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,102 | $44K |
| 84703 | <1% | 6,264 | $43K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 627 | $39K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,385 | $37K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 186 | $36K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,799 | $35K |
| 83690 | <1% | 5,896 | $35K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,194 | $35K |
| 73130 | <1% | 542 | $34K | |
| 81001 | <1% | 11,099 | $34K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,964 | $30K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,137 | $30K |
| 93971 | <1% | 263 | $29K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,411 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,704 | $23K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,430 | $22K |
| 73030 | <1% | 377 | $22K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,660 | $21K |
| 82553 | <1% | 1,714 | $21K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,073 | $20K |
| 71250 | <1% | 178 | $20K | |
| 83605 | <1% | 2,065 | $19K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,529 | $19K |
| 72040 | <1% | 246 | $18K | |
| 83735 | <1% | 2,913 | $16K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 408 | $16K |
| 82947 | <1% | 2,591 | $15K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 539 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 434 | $14K |
| 82550 | <1% | 2,261 | $14K | |
| 87077 | <1% | 1,689 | $14K | |
| 87081 | <1% | 1,711 | $12K | |
| 73560 | <1% | 173 | $11K | |
| 85610 | <1% | 3,128 | $11K | |
| 87040 | <1% | 944 | $11K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,285 | $11K |
| 85730 | <1% | 2,394 | $11K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,342 | $10K |
| 94060 | <1% | 103 | $10K | |
| 74018 | <1% | 291 | $10K | |
| 85379 | <1% | 1,086 | $10K | |
| 85027 | <1% | 1,431 | $10K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,101 | $9K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 15 | $8K |
| 94760 | <1% | 1,633 | $8K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,887 | $8K |
| 82565 | <1% | 596 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,249 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,449 | $7K |
| 90715 | <1% | 249 | $7K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 343 | $7K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 490 | $7K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 576 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 174 | $6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 47 | $5K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 92 | $5K |
| 82805 | <1% | 85 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 481 | $4K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 17 | $4K |
| 87186 | <1% | 517 | $4K | |
| 73110 | <1% | 62 | $4K | |
| 82150 | <1% | 585 | $4K | |
| 80061 | Lipid panel | <1% | 292 | $3K |
| 73562 | <1% | 33 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 379 | $3K |
| J3490 | Unclassified drugs | <1% | 696 | $3K |
| 86328 | <1% | 79 | $3K | |
| 93017 | <1% | 14 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 414 | $2K |
| 12001 | <1% | 25 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 330 | $2K |
| 97116 | <1% | 55 | $2K | |
| 93225 | <1% | 14 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 172 | $2K |
| 76536 | <1% | 14 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 238 | $2K |
| 81003 | <1% | 720 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 792 | $2K |
| 86141 | <1% | 191 | $2K | |
| 87210 | <1% | 388 | $2K | |
| 94726 | <1% | 29 | $2K | |
| 84145 | <1% | 65 | $1K | |
| 73080 | <1% | 16 | $1K | |
| 87807 | <1% | 97 | $1K | |
| 73502 | <1% | 21 | $1K | |
| 94729 | <1% | 47 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 289 | $987.68 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 26 | $960.29 |
| 84100 | <1% | 198 | $881.72 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 31 | $792.63 |
| 84702 | <1% | 52 | $777.58 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 251 | $776.27 |
| 88304 | <1% | 12 | $775.91 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 30 | $774.83 |
| 93922 | <1% | 13 | $644.29 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 26 | $599.47 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 36 | $476.04 |
| 86677 | <1% | 29 | $470.81 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 71 | $402.15 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 213 | $380.52 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 39 | $338.95 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 27 | $309.35 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 17 | $267.90 |
| 36600 | <1% | 15 | $252.43 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 31 | $146.26 |
| 80076 | <1% | 18 | $117.68 | |
| 93242 | <1% | 13 | $106.90 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 16 | $93.36 |
| 84439 | <1% | 12 | $83.61 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 12 | $80.15 |
| 84132 | <1% | 12 | $51.34 | |
| 86900 | <1% | 13 | $40.83 | |
| 86901 | <1% | 13 | $40.83 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 42 | $33.21 |
| A9270 | Non-covered item or service | 0% | 485 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, THOMAS (CEO)
| Provider | Location | Paid |
|---|---|---|
| Sandhills Eye Care, Od, PA | Fayetteville, NC | $175K |
| Chair City Family Medicine, PC | Gardner, MA | $58K |
| Crestview Physical Therapy INC | Crestview, FL | $48K |
| Roanoke Ambulatory Surgery Center, LLC | Roanoke, VA | $31K |
| Geriatric Consulting Group PC | Hendersonville, TN | $30K |
| Bluerad PLLC | Bluefield, WV | $10K |
| Access Wellness Resources | Fort Worth, TX | $3K |
| Uofl Health-Louisville INC | Louisville, KY | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.